Defucosylated Monoclonal Antibody (H₂Mab-139-mG_2a-f) Exerted Antitumor Activities in Mouse Xenograft Models of Breast Cancers against Human Epidermal Growth Factor Receptor 2.

ABSTRACT: The clinically approved human epidermal growth factor receptor 2 (HER2)-targeting monoclonal antibodies (mAbs), trastuzumab, and pertuzumab, target domains IV and II, respectively. Trastuzumab is now the standard treatment for HER2-overexpressed breast and gastric cancers, and trastuzumab in combination with pertuzumab showed clinical benefit. However, there still exist patients who do not respond to the therapy. Furthermore, HER2 mutants that cannot be recognized by pertuzumab were found in tumors. Therefore, novel anti-HER2 mAbs and modalities have been desired. In our previous study, we developed a novel anti-HER2 domain I mAb, H₂Mab-139 (mouse IgG₁, kappa). We herein produced a defucosylated mouse IgG_2a type of mAb against HER2 (H₂Mab-139-mG<

SUBMITTER: Suzuki H 

PROVIDER: S-EPMC10605610 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature